Skip to main content

Site notifications

We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.

Sub menu

News and events
Contact us
About us

Search

Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

You are here

Home
Resources and guidance
Sponsors

Juno Pharmaceuticals Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (261)
Cancellation by sponsor (83)
Prescription medicine registration (28)
Section 14, TGO91 consent (6)
Australian public assessment report (AusPar) (1)
Prescription medicine decision summary (1)

Date

2026 (3)
2025 (23)
2024 (13)
2023 (18)
2022 (35)
2021 (68)
2020 (45)
2019 (51)
2018 (18)
2017 (14)
2016 (17)
2015 (14)
2014 (7)
2013 (8)
2012 (12)
2011 (5)
2010 (1)
2009 (2)
2007 (1)
2006 (4)
2003 (7)
2000 (1)
1999 (2)
1998 (1)
1996 (3)
1994 (2)
1991 (5)

Search

Sponsor content

380 result(s) found, displaying 131 to 140

TOBRAMYCIN AMNEAL tobramycin 300 mg/5 mL inhalation solution ampoule Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
PEMETREXED ACT pemetrexed (as disodium) 100mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
PEMETREXED ACT pemetrexed (as disodium) 500mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
TIROSTAT tirofiban (as hydrochloride) 12.5mg/50mL Concentrated Injection for infusion Vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
IMATINIB AMNEAL imatinib (as mesilate) 400 mg capsules blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
IMATINIB AMNEAL imatinib (as mesilate) 100 mg capsules blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
JUNOXICLAV 500/100 amoxicillin (as sodium) 500 mg and clavulanic acid (as potassium clavulanate) 100mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
JUNOXICLAV 1000/200 amoxicillin (as sodium) 1000 mg and clavulanic acid (as potassium clavulanate) 200mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
JUNOXICLAV 2000/200 amoxicillin (as sodium) 2000 mg and clavulanic acid (as potassium clavulanate) 200mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
POSACONAZOLE JUNO posaconazole 100 mg modified release tablets blister pack (325700)

7 August 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for POSACONAZOLE JUNO posaconazole 100 mg modified release tablets blister pack.

Pages

First page
Previous page
…
Page 10
Page 11
Page 12
Page 13
Current page 14
Page 15
Page 16
Page 17
Page 18
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

© Commonwealth of Australia